Literature DB >> 33171476

The Minimal Clinically Important Difference in Glaucoma Medication Adherence: Interviews of Glaucoma Experts.

Ajay Kolli1, Shelby Daniel-Wayman2, Paula Anne Newman-Casey3.   

Abstract

Poor adherence to glaucoma medications is associated with progressive vision loss. While many interventions have sought to increase glaucoma medication adherence, the amount by which adherence must increase to have a clinically significant effect remains unknown. To generate a hypothesized minimal clinically important difference (MCID) for glaucoma medication adherence, we conducted interviews with glaucoma experts. Semi-structured interviews were conducted with members of the American Glaucoma Society. MCID was defined in 2 ways: (1) the incremental increase in the average percentage of eye drops a patient takes at roughly the correct time and (2) the incremental increase in the proportion of a patient population who attain good adherence. Good adherence was defined as taking more than 80% of drops at approximately the prescribed dose time. Expert opinions on the MCID for glaucoma medication adherence and open-ended responses were recorded through field notes. Twenty-five experts were interviewed. They estimated the MCID for average individual adherence levels as 17.7% (95% CI: 14.6, 20.8). Experts estimated the MCID for the proportion of patients in a practice who attain good adherence (defined as >80% of eye drops taken as prescribed) as 18.5% (95% CI: 15.6, 21.5). The most common identified themes were that the MCID should take into account the cost of the intervention and the burden to the ophthalmologist and to the practice, where experts thought that more costly interventions or those that required more physician time should have larger MCIDs. Based on expert opinion, we hypothesized that the MCID for glaucoma medication adherence is between 15 and 20%. However, the MCID for a given intervention must take into account several factors, including intervention cost and physician burden. This hypothesis may facilitate the design and implementation of future studies to objectively determine an MCID for glaucoma medication adherence.
© 2020 S. Karger AG, Basel.

Entities:  

Keywords:  Adherence; Glaucoma; Minimal clinically important difference

Mesh:

Substances:

Year:  2020        PMID: 33171476      PMCID: PMC9088219          DOI: 10.1159/000512924

Source DB:  PubMed          Journal:  Ophthalmic Res        ISSN: 0030-3747            Impact factor:   3.031


  22 in total

1.  Minimal clinically important difference: defining what really matters to patients.

Authors:  Anna E McGlothlin; Roger J Lewis
Journal:  JAMA       Date:  2014-10-01       Impact factor: 56.272

Review 2.  Interventions to improve adherence to inhaled steroids for asthma.

Authors:  Rebecca Normansell; Kayleigh M Kew; Elizabeth Stovold
Journal:  Cochrane Database Syst Rev       Date:  2017-04-18

3.  Correlates of attendance and compliance in the hypertension detection and follow-up program.

Authors:  N Shulman; G Cutter; R Daugherty; M Sexton; G Pauk; M J Taylor; M Tyler
Journal:  Control Clin Trials       Date:  1982-03

4.  Perspectives on patient-reported outcomes : content validity and qualitative research in a changing clinical trial environment.

Authors:  Nancy Kline Leidy; Margaret Vernon
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

5.  Compliance with prescribed drug therapy in asthma.

Authors:  M Yeung; S A O'Connor; D T Parry; G M Cochrane
Journal:  Respir Med       Date:  1994-01       Impact factor: 3.415

6.  Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial.

Authors:  M Cristina Leske; Anders Heijl; Mohamed Hussein; Bo Bengtsson; Leslie Hyman; Eugene Komaroff
Journal:  Arch Ophthalmol       Date:  2003-01

7.  Consequences and determinants of adherence to antiretroviral medication: results from Adult AIDS Clinical Trials Group protocol 370.

Authors:  Jeonnette R Ickovics; Ann Cameron; Robert Zackin; Roland Bassett; Margaret Chesney; Victoria A Johnson; Daniel R Kuritzkes
Journal:  Antivir Ther       Date:  2002-09

8.  ESPACOMP Medication Adherence Reporting Guideline (EMERGE).

Authors:  Sabina De Geest; Leah L Zullig; Jacqueline Dunbar-Jacob; Remon Helmy; Dyfrig A Hughes; Ira B Wilson; Bernard Vrijens
Journal:  Ann Intern Med       Date:  2018-06-26       Impact factor: 51.598

9.  A survey of attitudes of glaucoma subspecialists in England and Wales to visual field test intervals in relation to NICE guidelines.

Authors:  Rizwan Malik; Helen Baker; Richard A Russell; David P Crabb
Journal:  BMJ Open       Date:  2013-05-03       Impact factor: 2.692

10.  Improving adherence to glaucoma medication: a randomised controlled trial of a patient-centred intervention (The Norwich Adherence Glaucoma Study).

Authors:  Heidi Cate; Debi Bhattacharya; Allan Clark; Richard Fordham; Richard Holland; David C Broadway
Journal:  BMC Ophthalmol       Date:  2014-03-24       Impact factor: 2.209

View more
  2 in total

1.  The Effects of Topical Timolol and Latanoprost on Calculated Ocular Perfusion Pressure in Nonglaucomatous Volunteers.

Authors:  Ajay Kolli; Carol B Toris; David M Reed; Jesse Gilbert; Arthur J Sit; Vikas Gulati; Arash Kazemi; Shan Fan; David C Musch; Sayoko E Moroi
Journal:  J Ocul Pharmacol Ther       Date:  2021-10-04       Impact factor: 2.850

2.  Demographic, Clinical, and Psychosocial Predictors of Change in Medication Adherence in the Support, Educate, Empower Program.

Authors:  David J Miller; Leslie M Niziol; Angela R Elam; Michele Heisler; Paul P Lee; Kenneth Resnicow; David C Musch; Deborah Darnley-Fisch; Jamie Mitchell; Paula Anne Newman-Casey
Journal:  Ophthalmol Glaucoma       Date:  2021-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.